Dynabac
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
acute bacterial exacerbations
General Information
Dynabac, a member of the newer macrolide group of antibiotics,
has received approval for expanded coverage within certain
indications, including the treatment of acute bacterial
exacerbations of chronic bronchitis and uncomplicated skin and skin
structure infections. Dynabac remains a once-a-day therapy.
Side Effects
The most common side effects were gastrointestinal, including
abdominal pain, nausea, and diarrhea.
